This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks Insiders Love Right Now

United Therapeutics

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Another name to look at with some interesting insider buying is biotechnology and drugs player United Therapeutics (UTHR - Get Report), which is focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. This stock hasn't done much at all so far in 2012 with shares up just under 2%.

United Therapeutics has a market cap of $2.58 billion and an enterprise value of $2.41 billion. This stock trades at a cheap valuation, with a trailing price-to-earnings of 10.14 and a forward price-to-earnings of 9.60. Its estimated growth rate for this year is 27%, and for next year it's pegged at 7.7%. This is a cash-rich company, since the total cash position on its balance sheet is $408.97 million and its total debt is $268.16 million. After you back out the debt, United Therapeutics has a total of $140.81 million of cash on its books.

>>Hot Biopharma Stocks With Breakout Potential in 2012

The CEO just bought 3,960 shares, or about $189,000 worth of stock, at $47.95 per share. The same CEO also just bought 4,138 shares, or about $198,000 worth of stock, at $47.94 per share.

From a technical perspective, UTHR is currently trading above both its 50-day and 200-day moving averages, which is bullish. Since this stock hit a low of $40.34 in April, shares have started to uptrend strong and make higher highs and higher lows, which is bullish technical price action. That move is quickly pushing UTHR within range of triggering a major breakout trade.

If you're bullish on UTHR, then I would look for long-biased trades once this stock triggers a break out above some past overhead resistance at $49.13 to $49.17 a share with high-volume. Look for volume on that move that hits near or above its three-month average action of 724,127 shares. If we get that move soon, then UTHR will have a great chance of re-testing and possibly taking out its next significant overhead resistance levels at $51.12 to $51.98 a share.

I would simply avoid UTHR or look for short-biased trades if it fails to trigger that breakout, and then drops back below some near-term support at $47 to $46 a share with high-volume. If we get that action soon, then UTHR could re-test and possibly take out its 200-day moving average of $44.29, and its 50-day moving average of $43.82 a share.

United Therapeutics shows up on a list of Hot Biotech Stocks Traded by Hedge Funds.

To see more stocks with notable insider buying like Sonus Networks (SONS), CytRx (CYTR) and ZBB Energy (ZBB), check out the Stocks With Big Insider Buying portfolio on Stockpickr.

-- Written by Roberto Pedone in Winderemere, Fla.


Follow Stockpickr on Twitter and become a fan on Facebook.
At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Windermere, Fla., is an independent trader who focuses on stocks, options, futures, commodities and currencies. He is also an outside contributor to and maintains the website, which he sold to Blue Wave Advisors in 2008. Roberto studied International Business at The Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany.
6 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
HERO $4.15 -2.81%
PLCE $50.99 0.26%
SUMR $2.05 0.49%
XCO $1.21 -9.70%
UTHR $155.51 0.83%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs